Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tesamorelin
Drug ID BADD_D02168
Description Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Indications and Usage Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Marketing Status Prescription; Discontinued
ATC Code H01AC06
DrugBank ID DB08869
KEGG ID D06655
MeSH ID C479538
PubChem ID 16137828
TTD Drug ID D0UL9R
NDC Product Code 76112-711; 62064-241
Synonyms tesamorelin | TH9507 | TH-9507 | egrifta
Chemical Information
Molecular Formula C221H366N72O67S
CAS Registry Number 804475-66-9
SMILES CCC=CCC(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C)C(=O)NC(CC(=O)O)C(=O)NC(C)C(=O)NC(C(C)CC )C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC3=CC=C( C=C3)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NCC(=O )NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCC N)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC(C(C)CC) C(=O)NC(CCSC)C(=O)NC(CO)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(= O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O) O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(C)C(=O)NC(CCCNC(=N)N)C(=O)NC(C)C(=O)NC(CCCNC (=N)N)C(=O)NC(CC(C)C)C(=O)N
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain upper07.01.05.003--
Arthralgia15.01.02.001--
Blood creatine phosphokinase increased13.04.01.001--
Carpal tunnel syndrome17.09.02.001--Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Depression19.15.01.001--
Drug specific antibody present13.17.01.001--Not Available
Dyspepsia07.01.02.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015--Not Available
Injection site haemorrhage08.02.03.005; 12.07.03.005; 24.07.01.010--Not Available
Injection site irritation08.02.03.027; 12.07.03.027--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site pruritus08.02.03.013; 12.07.03.014; 23.03.12.007--Not Available
Injection site rash08.02.03.032; 12.07.03.032; 23.03.13.010--Not Available
Injection site reaction08.02.03.014; 12.07.03.015--
Injection site urticaria08.02.03.029; 10.01.06.003; 12.07.03.029; 23.04.02.003--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Joint stiffness15.01.02.003--Not Available
Joint swelling15.01.02.004--Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003--Not Available
Night sweats08.01.03.031; 23.02.03.006--Not Available
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pain08.01.08.004--
The 1th Page    1 2    Next   Last    Total 2 Pages